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Entry of influenza virus into the host cell is dependent on the fusion of the viral envelope with the endosomal membrane
and is mediated by a low-pH-induced change of the viral hemagglutinin (HA) to a conformation that is fusogenic. A compound
related to podocarpic acid (180299) was identified that inhibits multicycle replication of influenza A/Kawasaki/86 (H1N1) virus
in culture. Treatment of Madin–Darby canine kidney (MDCK) cells with 180299 at 1 h before infection resulted in the inhibition
of viral protein synthesis. Addition of 20 mg of 180299/ml at 1 h p.i. had no effect, indicating that 180299 affects an early step
of the influenza viral replication cycle. Genetic analysis of reassortants between sensitive and resistant viruses demon-
strated that hemagglutinin (HA) conferred the 180299-resistant (180299r ) phenotype. Twelve independent isolates of
influenza A/Kawasaki/86 were selected for resistance to 180299, and sequence analysis revealed that each of these viruses
contained amino acid substitutions in the HA. These mutations are dispersed throughout the HA primary amino acid
sequence and cluster in one of two regions: the interface between HA1 and HA2 and in a region near the fusion domain of
HA2. When compared with the parent virus, the pH-of-inactivation of the resistant mutants was increased by 0.3 to 0.6 pH
unit, suggesting that the mutant HAs undergo the conformational change at an elevated pH. Fusion of human erythrocytes
to MDCK cells infected with parent influenza A/Kawasaki/86 was inhibited by 180299 (0.1–10 mg/ml) in a concentration-
dependent manner, whereas fusion of erythrocytes to MDCK cells infected with 180299r mutants was not affected. These
results suggest that 180299 interacts with the neutral pH conformation of influenza A HA and prevents the low-pH-induced
change of HA to its fusogenic conformation. © 1998 Academic Press
INTRODUCTION
The entry of enveloped viruses into host cells involves
the fusion of viral and host cell membranes, a process
common to all enveloped viruses and absolutely re-
quired for productive influenza virus infection. For influ-
enza virus, this process is mediated by the envelope
glycoprotein hemagglutinin (reviewed by White, 1990).
The hemagglutinin (HA) of influenza virus carries out two
functions in the early stages of the viral life cycle. First,
HA contains a receptor binding site in the membrane
distal region that is responsible for binding of the virus to
sialylated glycoprotein receptors on the host cell. Sec-
ond, HA undergoes a low-pH-induced conformational
change within the host endosomal compartment and
mediates membrane fusion.
Extensive genetic, biochemical, and crystallographic
studies have provided a detailed understanding of the
structure and function of HA within the viral life cycle
(Wilson et al., 1981; Daniels et al., 1985; Carr and Kim,
1993; Bullough et al., 1994; also reviewed in White, 1990).
HA is synthesized as a precursor protein (HA0) and is
subsequently cleaved by a host cell protease to yield the
polypeptide subunits HA1 and HA2, which remain co-
valently linked by a single disulfide bond (reviewed in
Wiley and Skehel, 1987). Cleavage of HA to its subunits
is essential for virus replication and infectivity (Klenk et
al., 1975; Lazarowitz and Choppin, 1975). During viral
protein synthesis and maturation, HA is cotranslationally
inserted into a lipid bilayer, after which it undergoes
post-translational modification and oligomerization into a
trimer of identical subunits. At neutral pH, HA exists in a
metastable conformation that is present in the mature
virus particle and mediates cell receptor recognition dur-
ing the start of viral infection. After internalization, the
virus particle encounters an acidic environment within
the host cell endosomal compartment, the low pH of
which triggers a dramatic and irreversible structural re-
arrangement in HA. This results in the formation of a
more stable conformer of HA in which the hydrophobic
fusion domain is displaced from a buried location in the
metastable HA to a position that is displaced 100 Å
toward the target endosomal membrane (Carr and Kim,
1993; Bullough et al., 1994). This structural rearrange-
ment facilitates the insertion of the fusion peptide into
the endosomal membrane. In a step that is not well
understood, HA trimers hold viral and host membranes
in apposition in preparation for the fusion of the two
membranes enabling the release of viral RNP complexes
into the host cell cytoplasm.
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Because the low-pH-induced membrane fusion pro-
cess is essential for virus replication and infectivity and
is mediated by HA, a unique viral protein, this step in the
virus life cycle may represent a feasible target for the
selective chemotherapeutic intervention of infections
caused by influenza viruses (Daniels et al., 1985; Carr
and Kim, 1993). Indeed, several recent reports have de-
scribed various small molecule inhibitors of the fuso-
genic function of HA (Bodian et al., 1993; Luo et al., 1996,
1997; Hoffman et al., 1997). Here, we describe the inhi-
bition of HA-mediated membrane fusion by a compound
related to podocarpic acid (180299) and provide prelim-
inary biochemical and genetic evidence consistent with
the inhibition of the low-pH-induced conformational
change of HA. Influenza virus variants containing HA
with mutations that confer resistance to 180299 display
an elevated pH-of-inactivation, suggesting that the con-
formational switch of HA to the fusogenic form occurs at
a higher pH. Taken together, our results provide further
information concerning amino acids that are important
for the low-pH-induced conformational switch of HA.
RESULTS
Identification of an inhibitor of influenza virus
replication
A compound related to podocarpic acid and desig-
nated as 180299 (Fig. 1) was identified as a specific
inhibitor of influenza A viruses in tissue culture. The
effect of 180299 on multicycle influenza virus replication
was assessed using a standard plaque assay in Madin–
Darby canine kidney (MDCK) cells (Hayden et al., 1980)
and was found to be active against influenza A/Kawasaki
(H1N1) (EC50 5 0.01 mg/ml). Generally, 180299 was most
active against various H1N1 influenza A viruses but also
displayed activity (EC50 5 0.03 mg/ml) against influenza
A/Ann Arbor/1/57 (H2N2). In contrast, 180299 displayed
marginal or no inhibition of influenza A/WSN/33 (H1N1),
various H3N2 subtypes of influenza A, or influenza
B/Lee/40 virus replication (Table 1). A similar spectrum of
activity for 180299 was observed using a panel of influ-
enza A and B clinical isolates (data not shown).
The effects of 180299 and, for comparison, the M2 ion
channel inhibitor amantadine and the neuraminidase
inhibitor 4-GuDANA on influenza virus protein synthesis
were examined (Fig. 2). When MDCK cells were treated
with 180299 at concentrations of 0.1–20 mg/ml 1 h before
infection with influenza A/Kawasaki/86, viral protein syn-
thesis was inhibited in a concentration-dependent man-
ner. In contrast, when these cells were treated with 20
mg of 180299/ml 1 h p.i., no effect on viral protein syn-
thesis was observed. Amantadine (up to 100 mg/ml),
which is known to inhibit influenza virus replication at an
early stage, was used as a comparator, and results
similar to those for 180299 were obtained. In contrast,
the neuraminidase inhibitor 4-GuDANA, which acts at a
later stage in virus replication, had no effect when added
before or 1 h after virus infection, as expected.
Resistance to 180299 is determined by the HA
segment
To determine which influenza genome segment or
segments were responsible for the resistance of influ-
enza A/WSN/33 to 180299, reassortment experiments
were conducted. In these studies, influenza A/WSN/33
was inactivated and inoculated onto MDCK cells along
with influenza A/Kawasaki/86, which is sensitive to
180299. Restriction enzyme analysis of gene segment
cDNAs obtained from 180299r viruses was performed to
FIG. 1. Chemical structure of methyl-O-methyl-7-ketopodocarpate
(180299).
TABLE 1
Summary of Data
Virus EC50
a DpH b RBC fusion assay
A/Kawasaki/86 0.01 1
A/Ann Arbor/1/57 0.03 10.2 1
B/Lee/40 4.36 10.2 ndc
A/Aichi/2/68 .10 10.4 2
A/WSN/33 .10 10.4 2
R(HA)d .5 10.6 2
A1 .10 10.4 nd
A2 .10 10.5 2
A3 .10 10.5 2
A4 .10 10.5 2
A5 .10 10.4 nd
A6 .10 10.3 2
A7 .10 10.4 2
A8 .10 10.6 2
A9 .10 10.4 nd
A10 .10 10.6 nd
a Activity is reported in mg/ml and is determined by plaque assay as
described in Materials and Methods.
b The difference in the pH-of-inactivation between the indicated virus
and A/Kawasaki/86 (4.8 6 0.1).
c Not determined.
d R(HA) is a reassortant virus with an HA from A/WSN/33 in an
A/Kawasaki/86 background.
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determine the parentage of each segment. Six reassor-
tant viruses were analyzed in this way (Fig. 3). In one
isolate, the WSN segments were NS, NA, and HA. In
three of the six isolates, the WSN segments consisted of
NA and HA. Two isolates contained only WSN HA, dem-
onstrating that the HA segment from the resistant
A/WSN/33 is necessary and sufficient to confer the drug-
resistant phenotype.
Selection and genetic characterization of 180299r
mutants
Twelve independent isolates of influenza A/Kawasaki/86
were selected for growth in a high concentration of
180299 (5 mg/ml) using a single passage protocol as
described in Materials and Methods. These viruses were
characterized by sequence analysis of the HA gene seg-
ment. All 180299r viruses contained at least one nucleo-
tide alteration leading to an amino acid substitution in
the HA (Table 2). In most cases, no correlation of primary
amino acid sequence with sensitivity to 180299 was
observed (Fig. 4). However, the presence of L30 in HA1
did correlate with sensitivity to 180299.
The amino sequence of HA from influenza A/Ka-
wasaki/86 was compared to that of influenza A/Aichi/
2/68 (H3N2) for which an x-ray crystallographic structure
is available (Wilson et al., 1981). The amino acids on the
H3 structure that correspond to those found altered in
the 180299r mutants were identified and are shown in
Fig. 5A. The mutations found in the HA segment of
resistant mutants are clustered into two regions: (1) the
interface between HA1 and HA2, critical for maintaining
the integrity of the metastable structure at neutral pH
(Daniels et al., 1985); and (2) near the fusion domain of
HA2. The majority of those amino acids which are altered
in 180299r mutants are buried within the interior of the
HA trimer (Fig. 5B).
FIG. 2. Viral protein synthesis in the presence of the 180299, amantadine, or 4-GuDANA. MDCK cells were treated with 180299, amantadine, or
4-GuDANA for 1 h before infection with influenza A/Kawasaki/86. Alternatively, compounds were added 1 h p.i. at the concentrations indicated.
Infected cells were pulse-labeled with [35S] for 30 min as described in Materials and Methods. Labeled proteins were analyzed by SDS–PAGE
followed by autoradiography.
FIG. 3. Resistance to 180299 is conferred by the influenza A/WSN/33
HA segment. MDCK cells were coinfected with the 180299s strain
A/Kawasaki/86 and the 180299r strain A/WSN/33 in the absence of
180299. Supernatant from the infected cells was used to infect MDCK
cells in the presence of 5 mg of 180299/ml. Viral plaques were picked
and expanded for further analysis. Plus-strand cDNA was synthesized
from vRNA that was isolated from six 180299r reassortants. After am-
plification by PCR, restriction analysis was used to determine the origin
of each segment. The parentage of each segment is indicated (Kaw 5
influenza A/Kawasaki/86; WSN 5 influenza A/WSN/33).
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Determination of the pH-of-inactivation of wild-type
and 180299r viruses
Treatment of influenza virions with low pH buffer leads
to the loss of infectivity (Guinea and Carrasco, 1995) due
to the change in the conformation of HA to the fusogenic
state, resulting in the inability to attach to and penetrate
the cell. The pH at which this conformational change
occurs varies with the viral strain in question (Maeda and
Ohnishi, 1980; Huang et al., 1981; White et al., 1981).
Consequently, each influenza virus strain has a charac-
teristic pH-of-inactivation (i.e., the pH at which virus in-
fectivity is lost). Whole virions were incubated in buffer at
pH values of 4.2–7.0, after which residual infectivity was
assessed by viral plaque assay. The pH at which infec-
tivity was reduced by 50% was determined as described
in Materials and Methods and compared with that of the
180299s strain A/Kawasaki/86. The pH dependence of
virus inactivation of wild-type A/Kawasaki/86 and several
180299r variants (A2, A4, A8, and A10) is shown in Figure
6A-D. Data for these variants and others are summarized
in Table 1, in which 180299r influenza viruses displayed
an elevated pH-of-inactivation from 10.3 to 10.6 pH unit.
The naturally resistant viruses A/WSN/33, A/Aichi/2/68,
and B/Lee/40 also displayed elevated pH-of-inactivation
values. In general, resistance to 180299 correlates with a
higher pH-of-inactivation value.
180299 inhibits HA-mediated fusion of human
erythrocytes with influenza virus-infected MDCK cells
MDCK cells were infected at a high m.o.i. with influ-
enza A/Kawasaki/86, which is susceptible to 180299.
When HA was expressed on the cell surface, as deter-
mined by red blood cell (RBC) binding, the cells were
treated with 180299 at concentrations of 0.1–10 mg/ml,
100 mg of amantadine/ml, or 20 mg of 4-GuDANA/ml. In
control experiments, cells were treated with preimmune
rabbit serum or antiserum to influenza A/Kawasaki/86.
After treatment with compounds or antiserum, the cells
were treated with pH 7 or 5 buffer at room temperature
for 10 min, after which the cells were fixed and stained.
Fusion of RBCs to MDCK cells was evaluated by visual
examination of the cultures. Fusion was inhibited by
180299 in a concentration-dependent manner (Fig. 7,
D–G) and was not affected by amantadine or 4-GuDANA
(Fig. 7, H and I). As expected, fusion was inhibited by
antiserum to influenza A/Kawasaki/86 (Fig. 7L). Also as
expected, HA-mediated fusion of human erythrocytes
necessitated prior treatment with trypsin (Fig. 7J), which
is required for the cleavage of HA0 to HA1 and HA2.
180299 does not inhibit fusion of human erythrocytes
to MDCK cells infected with naturally resistant influenza
viruses or influenza viruses selected for resistance to
180299. In similar experiments, 180299 was shown to
inhibit the fusion of RBCs to MDCK cells infected with
TABLE 2
Amino Acid Substitutions in 180299r Mutants
Mutant HA1 HA2
A1 G266R (S)a —
A2 — F110S (L)
A3 L30H/F79L/M316I (T,F,L) —
A4 V7Ib T107I (T)
A5 — F110S (L)
A6 — A65D (Q)
A7 L30F/I70V (T,L) —
A8 E106G (A) D112N (D)
A9 G266R/M316I (S,L) —
A10 — T107I (T)
JT.Bc A259V (K) A65V (Q)
3-1 K163N/G225D (V,G) A96T/N117D (A,K)
a The residue numbers indicated for A/Kawasaki/86 mutants are
those of the corresponding amino acids in the HA of A/Aichi/2/68,
which are given in parentheses.
b A/Kawasaki/86 numbering.
c JT.B is resistant to the oxime derivative of the ketone 180299.
FIG. 4. Sequence comparison of various influenza virus HAs. The signal peptide (SP) and the fusion and transmembrane (TM) domains are
indicated. The coordinates (H3 numbering) of the amino acids found substituted in the 180299r mutants are indicated in bold. The corresponding
amino acids in A/WSN/33 (H1), A/Japan/3051/57 (H2), A/Aichi/2/68 (H3), and B/Lee/40 are shown for comparison. Amino acids in bold are absolutely
conserved among all influenza HAs.
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influenza A/Kawasaki/86 or A/Ann Arbor/1/57, both of
which are susceptible to this compound (Fig. 8). In con-
trast, fusion induced by the naturally resistant strains of
influenza (A/WSN/33 and A/Aichi/2/68) or mutants of
A/Kawasaki/86 selected for resistance to 180299 (A2, A4,
A7, and A8) was not affected by 180299 (Fig. 9).
DISCUSSION
In this report, we characterize the anti-influenza activ-
ity of a compound (180299) derived from podocarpic acid.
Genetic analysis of reassortants between a strain (A/
Kawasaki/86) that is naturally sensitive to 180299 and a
strain (A/WSN/33) that is naturally resistant to 180299
demonstrated that the HA segment from the resistant
strain was necessary and sufficient to confer the 180299r
phenotype. Variants of A/Kawasaki/86 were selected for
resistance to 180299 and characterized genetically by
sequence analysis of the HA gene segment. All resistant
variants contained at least one amino acid alteration in
the HA. In addition, one variant, designated JT.B, was
selected for resistance to the oxime derivative of 180299
and also contained sequence alterations in HA (Table 2).
Using primary amino acid sequence alignments, the
amino acids present in the HA of A/Aichi/2/68 that cor-
respond to those amino acids found substituted in the
180299r A/Kawasaki/86 mutants were identified and lo-
cated on the three-dimensional structure of HA. Although
a correlation between sensitivity to 180299 and primary
amino acid sequence is not immediately obvious, the
majority of the amino acid substitutions are buried in the
three-dimensional structure. In addition, the mutations
cluster in two regions: (1) the interface between HA1 and
HA2 and (2) near the fusion peptide of HA2. This sug-
gests that these mutations may have a destabilizing
effect on the native, metastable conformation of HA, as
has been described for mutations in the HA of influenza
A virus selected for resistance to high concentrations of
amantadine (Daniels et al., 1985), tert-butylhydroquinone
(TBHQ) (Hoffman et al., 1997), and 4-amino-5-chloro-2-
hydroxy-N-9-AaH-octahydro-6b-methyl-2H-quinolizin-2a-
benzamide (BMY 27709) (Luo et al., 1997).
Previous work has shown that in cell culture me-
dium at pH ,5.5, entry of influenza virus can take
place at the level of the plasma membrane, circum-
venting the normal endosomal route of entry (Matlin et
al., 1981; Yoshimura et al., 1982). More recently, it was
shown that incubation of cell-free influenza virus in
acidic medium leads to an irreversible loss of HA-
mediated membrane fusion activity (Maeda et al.,
1981; Skehel et al., 1982; Sato et al., 1983; White et al.,
1982) and to a significant drop in infectivity (Guinea
and Carrasco, 1995), presumably due to a premature
conformational change in HA to its fusogenic state.
Indeed, electron microscopy of low-pH-inactivated in-
fluenza virus reveals aggregates of viruses that con-
tain HA molecules with the fusion peptide region most
likely inserted into other viral membranes (Kanaseki et
al., 1997; Sato et al., 1983, Weber et al., 1994; Wharton
et al., 1995). Prompted by these observations, we
asked whether amino acid substitutions in the HA of
180299r variants would affect the pH at which the virus
is inactivated. The pH-of-inactivation of the selected or
reassortant 180299r viruses was higher than that of the
FIG. 5. Location of amino acid substitutions found in the HA of
180299r influenza viruses. (A) Ribbon diagram of the bromolain cleaved
H3 monomer (BHA). The HA1 (green) and HA2 (yellow) chains are
indicated. The amino acid sequence of the HA from A/Aichi/2/68 and
A/Kawasaki/86 were aligned using BestFit (GCG, version 8.1, Genetics
Computer Group, Madison, Wisconsin), and the amino acids that cor-
respond to those found substituted in the HA of the 180299r mutants
are shown in red. (B) View from the membrane distal region of the BHA
trimer.
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parent A/Kawasaki/86 virus. Of interest is the obser-
vation that influenza A/Kawasaki/86, the most sensi-
tive to the antiviral activity of 180299 (EC50 5 0.01
mg/ml), had the lowest pH-of-inactivation (4.8) (Table
1). Furthermore, influenza viruses that are naturally
resistant to 180299 (A/Aichi/2/68, A/WSN/33, and
B/Lee/40) displayed, in general, an elevated pH-of-
inactivation. These results suggest that the transition
of the HA of the resistant viruses from the nonfuso-
genic conformer to the fusogenic conformer occurs at
FIG. 7. Effect of 180299 on HA-mediated membrane fusion. Fusion of human erythrocytes to A/Kawasaki/86-infected MDCK cells after incubation
at pH 7.0 (a and b) or pH 5.0 (c–l). MDCK cells were treated as described in the Materials and Methods. (a) Uninfected control, pH 7.0. (b) Infected,
untreated control, pH 7.0. (c) Infected, untreated control, pH 5.0. (d) Infected, 180299 (0.01 mg/ml), pH 5.0, (e) Infected, 180299 (0.1 mg/ml), pH 5.0. (f)
Infected, 180299 (1.0 mg/ml), pH 5.0. (g) Infected, 180299 (10 mg/ml), pH 5.0. (h) Infected, amantadine (100 mg/ml), pH 5.0. (i) Infected, 4-GuDANA (20
mg/ml), pH 5.0. (j) Infected, no trypsin, pH 5.0. (k) Infected, preimmune rabbit serum, pH 5.0. (l) Infected, a-HA/Kawasaki/86 antiserum, pH 5.0.
FIG. 8. Effect of 180299 on the fusion of human erythrocytes to MDCK cells infected with various influenza viruses. MDCK cells were infected with
influenza A/Kawasaki/86, A/Ann Arbor/1/57, A/WSN/33, or A/Aichi/2/68 as indicated. At 8 h p.i., the HA present on the surface of the infected cells
was cleaved with trypsin and the cells were incubated with or without 180299 (10 mg/ml) for 5 min at room temperature. Treatment with pH 5.0 buffer
was as described in the Materials and Methods.
FIG. 9. Effect of 180299 on the fusion of human erythrocytes to MDCK cells infected with 180299r influenza viruses. MDCK cells were infected with
180299r A/Kawasaki/86 influenza virus variants as indicated. The compound 180299 (10 mg/ml) was added at ;8 h p.i. Fusion of human erythrocytes
was monitored at the indicated pH as described in Materials and Methods.
FIG. 6. The pH-of-inactivation profiles of wild-type and selected variants of 180299r influenza A/Kawasaki/86. Wild-type (F) or 180299r variants ()
of influenza A/Kawasaki/86 were treated at the indicated pH as described in Materials and Methods. The residual infectivity after treatment was
determined by plaque assay. The percent inactivation at each pH was determined in separate experiments each performed in duplicate. The average
value was plotted in each case and fitted transition curves are shown. (A), Variant A2; (B), variant A4; (C), variant A8; and (D), variant A10.
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an elevated pH. However, to address this possibility,
studies that monitor the transition of HA more directly
will be necessary.
Earlier work demonstrated that influenza viruses
that contain an altered hemagglutinin can be selected
in response to agents that elevate endosomal pH. For
example, the antiparkinsonism compound norakin
(triperiden) was shown to inhibit influenza virus infec-
tivity if present before virus infection, indicating that
this compound targets an early step in virus replica-
tion (Presber et al., 1984). Subsequently, influenza vi-
rus variants were selected for resistance to norakin
and were found to have mutations in the HA molecule,
the majority of which were in HA2 (Prosch et al., 1988,
1990). Of interest was the change at D112 to G or Y in
the HA of norakinr influenza viruses (Prosch et al.,
1990), since we observed a change of D to N at that
same position in the HA of one 180299r influenza virus
(A8, Table 2). More recently, it was demonstrated that
norakin inhibits influenza virus replication by elevating
prelysosomal pH, thus preventing the conformational
transition of HA to its fusogenic state (Ott and
Wunderli-Allenspach, 1994). These results suggest
that HA from norakin-resistant viruses can undergo
this transition at a higher pH than can wild-type virus.
Resistance to antiviral concentrations of the M2 ion
channel inhibitor amantadine maps to mutations in the
M2 gene segment (reviewed in Hay, 1992). However,
when used at high concentrations (100 mg/ml), amanta-
dine, a basic tertiary amine, can elevate the pH of the
endosome (Hay et al., 1985). Influenza viruses that are
resistant to high concentrations of amantadine contain
sequence alterations in the HA that are found in two
clusters: (1) near the amino-terminal fusion peptide, re-
sulting in a destabilization of the pH 7 conformer; and (2)
at intersubunit contacts, resulting in their disruption
(Daniels et al., 1985). Both types of mutations result in an
HA molecule that can undergo the conformational switch
at an elevated pH. In particular, these mutants contained
a change in the HA at D112 (Daniels et al., 1985), an
alteration that has subsequently been described for
norakinr influenza viruses (Prosch et al., 1990), TBHQr
(Hoffman et al., 1997), and, as reported here, 180299r
influenza viruses. Structural analysis of an HA molecule
containing the D112G mutation revealed a loss of intra-
chain hydrogen bonds that stabilize the amino-terminal
fusion peptide in wild-type HA (Weis et al., 1990). The
alteration at D112 in response to agents that elevate
endosomal pH or to agents that may interact with HA to
stabilize the neutral pH conformer, as will be discussed
below, indicate the critical role this region plays in the
low-pH-induced conformational switch of HA.
In light of results obtained with norakin or high con-
centrations of amantadine, the question was addressed
of whether 180299 affected virus entry by altering endo-
somal pH or by a more direct effect on the HA. To this
end, using an infected-cell/RBC fusion assay, it was
demonstrated that 180299 prevented HA-mediated fu-
sion in a concentration-dependent fashion, indicating a
direct effect on the fusogenic function of HA. Further-
more, the ability of 180299 to prevent RBC fusion corre-
lated with its ability to inhibit virus replication. For exam-
ple, 180299 did not prevent fusion of RBCs to cells
infected with viruses selected for 180299 resistance or
with viruses that are naturally resistant to 180299. Thus,
it is unlikely that the mechanism underlying the effect of
180299 on influenza virus replication is merely a result of
the alteration of endosomal pH.
Other compounds have been reported to inhibit influ-
enza virus replication by interfering with the fusogenic
function of HA. Using the DOCK program, compounds
were selected for their predicted ability to bind to the pH
7 or metastable, conformation of HA. One such com-
pound, TBHQ, was identified and found to inhibit the
conformational change in HA from influenza X31. TBHQ
has anti-influenza activity in cell culture in the micromo-
lar range (Bodian et al., 1993), and influenza virus vari-
ants that are resistant to TBHQ contained mutations in
the HA (Hoffman et al., 1997).
Another group showed that BMY 27709 inhibited the
replication of influenza A subtypes H1 and H2 but not
that of influenza A subtype H3 or influenza B virus. This
compound was able to inhibit HA-mediated RBC hemo-
lysis, suggesting a block in the fusogenic function of HA
(Luo et al., 1996). Genetic analysis of variants that are
resistant to BMY 27709 demonstrated that amino acid
changes occurred in a region of the HA gene near the
amino terminus of HA2, the fusion peptide. One mutation
in particular was identical to that found in 180299r influ-
enza viruses, namely F110S, which is located in the HA2
subdomain. This mutation resulted in a 0.3-unit elevation
of the pH of RBC hemolysis (Luo et al., 1997). Similarly,
the F110S mutation in 180299r influenza A virus elevated
the pH-of-inactivation by 0.4 unit. The changes in BMY
27709r HA suggested a drug-binding pocket within the
molecule. It was therefore suggested that BMY-27709
inhibits HA-mediated fusion as a result of binding within
the HA molecule via specific interactions (Luo et al.,
1997). In like fashion, 180299 may interact with the native
or metastable conformation of HA in such a way as to
prevent the conformational switch to the fusogenic state.
It is conceivable that 180299 may bind to the HA mole-
cule in a specific or nonspecific way in the regions of the
protein important for this conformational switch. Some of
these regions may be those identified by amino acid
alterations found in the HA of 180299r variants. However,
experiments designed to determine whether 180299
binds directly to HA will be necessary to address this
possibility.
Although results obtained with BMY 27709 and
180299 are apparently similar, the observation that the
former compound is active against A/WSN/33 whereas
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180299 is not points to a potential difference in the
way these compounds may interact with various influ-
enza HA molecules. Regardless, the end result of the
inhibition of the conformational change of HA by either
compound is the inhibition of membrane fusion and,
thus, virus replication.
More recently, using structure-based drug design, new
inhibitors of HA-mediated fusion, belonging to several
chemical classes, have been selected by DOCK and
have been shown to possess anti-influenza activity (Hoff-
man et al., 1997). One compound in particular, C22, was
shown to facilitate the low-pH-induced conformational
change in HA to the fusogenic state. Resistance to C22
was correlated with changes in the HA molecule that
stabilized the pH 7 (metastable) conformation as evi-
denced by a lower pH-of-hemolysis. Consequently, C22
was more active against TBHQr viruses than against
wild-type viruses (Hoffman et al., 1997). Therefore, it
would be of interest to determine whether C22 is more
active against 180299r or BMY 27709r influenza viruses
than against wild-type influenza viruses.
Because 180299r mutants have a higher pH-of-inacti-
vation, the amino acid changes we have observed, par-
ticularly those that have also been observed by others in
fusion mutants (Daniels et al., 1985), in norakinr influenza
viruses (Prosch et al., 1988, 1990), in BMY 27709r mutants
(Luo et al., 1997), or in TBHQr mutants (Hoffman et al.,
1997), most likely lead to alterations in the interaction
between subunits of the trimer. This in turn may lead to
an elevation of the pH optimum for fusion (i.e., the con-
formational transition of HA). It has been postulated by
others (Daniels et al., 1985) that these amino acid
changes most likely lower the activation energy required
to expose the amino-terminal peptide of HA2 or alter the
interaction between subunits, which results in a lower
concentration of protons required to trigger the confor-
mational change. Although the exact amino acids that
participate in salt bridges or contain ionizable groups
that are involved in the conformational switch are un-
known (Daniels et al., 1985), it appears that several
amino acids are involved in the conformational switch.
The diverse nature of compounds that have been re-
ported to interfere with this transition provides us with a
number of probes to study this process in greater mo-
lecular detail.
MATERIALS AND METHODS
Cell culture and compounds
MDCK cells were maintained in Earle’s MEM containing
10% FBS. Influenza virus plaque assays were performed
according to Hayden et al. (1980). The EC50 values were
calculated according to Reed and Muench (1938). The
neuraminidase inhibitor 4-guanidino-Neu5Ac2en (4-
GuDANA) was synthesized according to published proce-
dures with modifications (von Itzstein et al., 1993; von
Itzstein et al., 1994). The podocarpic acid derivative methyl-
O-methyl-7-ketopodocarpate (Lilly serial number 180299;
Fig. 1), was synthesized from the natural product podo-
carpic acid in two steps by the method of Parish and Miles
(1984). Alternatively, methyl-O-methylpodocarpate (Aldrich
Chemical Company, Milwaukee, WI) was oxidized by chro-
mium trioxide to 180299 (Parish and Miles, 1984). Amanta-
dine was purchased from the Aldrich Chemical Company.
For pH-of-inactivation studies, viral stocks were diluted se-
rially in MEM medium ranging in pH from 4.2 to 7.0 in
increments of 0.1 unit. After incubation at 37°C for 15 min,
virus titers were determined by plaque assay as described
above. The pH-of-inactivation data were fit to smooth tran-
sition curves using the statistical package JMP (SAS Insti-
tute, Cary, North Carolina), and the point at which 50% of the
virus was inactivated was recorded.
Pulse-labeling studies
Confluent monolayers of MDCK cells were infected
with influenza A/Kawasaki/86 at a m.o.i. of ;10. Com-
pounds were added either 1 h before or 1 h after infec-
tion as indicated. Compounds, at the indicated concen-
trations, were present during infection and in the labeling
medium. After a 2-h incubation at 37°C, the infected
monolayers were incubated with labeling medium con-
sisting of DMEM (lacking L-cysteine and L-methionine)
containing 10 mM HEPES, 1 mM sodium pyruvate, 2 mM
L-glutamine, and 10 mM MES, pH 7.0, for 30 min. The
cells were then incubated in labeling medium containing
50 mCi of Pro-mix L-[35S] in vivo cell labeling mix (Amer-
sham Corporation, Arlington Heights, Illinois) at 37°C for
30 min. The infected cell monolayers were rinsed twice
with PBS, lysed in Laemmli’s buffer, and analyzed by
SDS–PAGE. Gels were fixed in 40% methanol/10% glacial
acetic acid, soaked in Enlightening (NEN Research Prod-
ucts, Boston, Massachusetts) for 30 min, dried under
vacuum, and exposed to x-ray film.
Isolation and genetic characterization of reassortants
MDCK cells were coinfected with 180299-sensitive
(180299s) A/Kawasaki/86 and UV-inactivated 180299r
A/WSN/33 and incubated at 37°C for 48–72 h. The
resulting virus in the supernatant was plaqued on
MDCK cells in the presence of 5 mg of 180299/ml. After
plaque purification, six 180299r reassortants were ex-
panded for genetic characterization. After centrifuga-
tion, virus pellets were resuspended in STE (0.1 M
NaCl, 0.01 M Tris–HCl, pH 7.4, 0.001 M EDTA). Viral
samples were digested in 10 mM Tris (pH 7.4), 10 mM
KCl, 1.5 mM MgCl2, 0.2% SDS, and 220 mg/ml Protein-
ase K at 56°C. After a 20-min incubation at 56°C, 80 ml
of 1 M NaCl and 0.5 ml of phenol/CHCl3/isoamyl alco-
hol (25:24:1) were added. The samples were vortexed
vigorously and incubated at 56°C for 5 min with occa-
sional vortexing. The aqueous phase was collected by
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centrifugation at room temperature and reextracted
with CHCl3/isoamyl alcohol (24:1). The extracted viral
RNA (vRNA) was precipitated by adding 0.1 volume of
3.0 M sodium acetate (pH 4.8) and 2.5 volumes of
ethanol and incubated overnight at 220°C. The vRNA
was collected by centrifugation, and pellets were
washed once with 70% ethanol, dried, and resus-
pended in nuclease-free water. The vRNA (5 mg) was
converted to plus-strand cDNA using 10 pmol of seg-
ment-specific primer and MMLV reverse transcriptase
according to the manufacturer’s protocol (Superscript
Preamplification System, GIBCO BRL, Gaithersburg,
Maryland). The cDNAs were amplified by polymerase
chain reaction containing 5 ml of plus-strand cDNA, 20
mM Tris–HCl (pH 8.4), 50 mM KCl, 200 mM dNTP, 250
nM concentration of primers, and 2.5 units of Taq DNA
polymerase (GIBCO BRL) in a total volume of 100 ml.
The thermocycler profile used was as follows: 1 cycle
at 95°C for 5 min, 30 cycles at 94°C for 45 s, 55°C for
30 s, and 72°C for 90 s. To determine the origin of each
segment, the PCR products were characterized by
restriction analysis.
Selection and sequence analysis of 180299r mutants
MDCK cells were infected with virus obtained from a
single plaque of A/Kawasaki/86 in the presence of 5 mg
of 180299/ml and incubated at 37°C for 48–72 h. Resis-
tant viruses were plaque purified in the presence of 5 mg
of 180299/ml and expanded for sequence analysis. Iso-
lation of vRNA, plus-strand cDNA synthesis, and PCR
amplification of the HA segment were carried out as
described above. HA cDNAs were sequenced by
dideoxy DNA sequencing using a PCR cycle sequencing
kit according to the manufacturer’s instructions (GIBCO
BRL). Oligonucleotides used for plus-strand cDNA syn-
thesis, PCR amplification, and sequencing were synthe-
sized on a Beckman OLIGO 1000 DNA synthesizer. The
sequences of these oligonucleotides are available on
request. Amino acid sequence alignments between the
HA of A/Kawasaki/86 and HAs of A/WSN/33, A/Japan/
3051/57, A/Aichi/2/68, and B/Lee/40 were made using
PileUp (GCG Package, version 8.1, Genetics Computer
Group, Madison, Wisconsin). The ribbon diagram shown
in Figure 5A was generated using RIBBONS (Carson,
1987), and the structural diagram shown in Figure 5B
was produced using QUANTA (Molecular Simulations,
Inc., San Diego, California).
Human erythrocyte fusion
Confluent monolayers of MDCK cells were infected at
37°C for 1 h with A/Kawasaki/86 at a m.o.i. of ;25. The
monolayer was rinsed twice with MEM medium contain-
ing 0.2% bovine albumin (BA) and replaced with the
same. After a 6- to 8-h incubation at 37°C, the monolayer
was rinsed once with PBS and then incubated at 37°C
for 5 min with PBS containing 2.5 mg/ml TPCK-treated
trypsin (Sigma Chemical, St. Louis, Missouri). The mono-
layers were then rinsed with PBS, and a solution of 0.05%
human erythrocytes in PBS was added. After a 10-min
incubation at room temperature, the monolayers were
washed extensively with PBS (3–5 times) until all un-
bound erythrocytes were washed from the uninfected
control monolayer. The infected cell monolayer was ob-
served for the presence of bound erythrocytes. Com-
pounds were added after binding of erythrocytes as
indicated. Monolayers were then incubated with MEM
medium adjusted to the appropriate pH with HCl or
buffer containing 150 mM NaCl and 20 mM NaOAc at the
indicated pH. After a 10-min incubation, the medium was
replaced with MEM at neutral pH or PBS, and the mono-
layers were incubated at 37°C for 5 min. Cell monolayers
were monitored visually for fusion of infected MDCK cells
with bound human erythrocytes. Cell monolayers were
fixed with a solution containing 1% formaldehyde and
0.2% glutaraldehyde in PBS at room temperature for 5
min, rinsed twice with PBS, and stained with Prussian
blue according to the manufacturer’s instructions (AC-
CUSTAIN Iron Stain, Sigma Chemical). Phase-contrast
photomicrographs were taken at 2003 magnification.
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